Long-term evolution of cytophagic histiocytic panniculitis.
BACKGROUND
Cytophagic histiocytic panniculitis is a disorder manifested by multiple subcutaneous nodules, characterized by lobular panniculitis, and occasionally accompanied by severe systemic manifestations, which require an aggressive medical approach. Several case reports with a good response to immunosuppressive therapy in the acute phase can be found in the literature.


CONCLUSIONS
Nevertheless, the long-term evolution of this entity has not been described yet, nor have precise recommendations regarding the most adequate posology and duration of therapy. We report the result of switching from a long-term cyclosporine therapy to tacrolimus in a patient with a severe form of cytophagic histiocytic panniculitis.
Rios Fernández
Raquel
R
Autoimmune Diseases Unit and Department of Pathology, Hospital Clinico de San Cecilio, Granada, Spain.
Callejas Rubio
José-Luis
JL
Sánchez Cano
Daniel
D
Dominguez Vicent
Juan-Ramón
JR
Linares Solano
Juan
J
Ortego Centeno
Norberto
N
D005260:Female; D006644:Histiocytes / Q000473:pathology; D015614:Histiocytosis / Q000473:pathology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008875:Middle Aged; D015434:Panniculitis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D011241:Prednisone / Q000008:administration & dosage; D016559:Tacrolimus / Q000008:administration & dosage*
D007166:Immunosuppressive Agents; D011241:Prednisone; D016559:Tacrolimus